ReviewToxins2018
The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 100 citations in OpenAlex.
- Combined Docosahexaenoic Acid and Captopril Treatment Attenuates Indole Acetic Acid Induced Cardiovascular Injury in Chronic Kidney Disease.Molecular nutrition & food research · 2026Article
- Neuro-Renal Crosstalk Across the Chronic Kidney Disease Spectrum: Stage-Dependent Molecular Mechanisms of Cognitive Impairment-An Integrative Review.International journal of molecular sciences · 2026Review
- The Kidney-Brain Axis in Chronic Kidney Disease: Uremic Toxins, Cognitive Decline, Mechanistic Pathways, Biomarkers and Therapeutic Perspectives.Biomedicines · 2026Review
- Dialysis disequilibrium syndrome: an underdiagnosed condition? Results from a monocentric observational study.Clinical kidney journal · 2026Article
- Impact of chronic kidney disease stage on seizure frequency and severity in pediatric epilepsy patients.BMC nephrology · 2026Article
- Mortality trends for chronic kidney disease and dementia in the United States, 1999-2020: a 22-year retrospective analysis.Annals of medicine and surgery (2012) · 2026Article
- The Spectrum of Motor Disorders in Patients with Chronic Kidney Disease: Pathogenic Mechanisms, Clinical Manifestations, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Association between protein-energy wasting and cognitive impairment in maintenance hemodialysis patients.Frontiers in nutrition · 2026Article
- Causality of blood metabolites and narcolepsy type 1: A Mendelian randomization study.Medicine · 2025Article
- Article
- Association of Phenylacetylglutamine and Cognitive Impairment in CKD.Kidney international reports · 2025Article
- Drivers and mechanisms of cognitive decline in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management.Clinical and experimental nephrology · 2025Review
- Article
- Neuroprotective Effects of Sodium Nitroprusside on CKD-Induced Cognitive Dysfunction in Rats: Role of CBS and Nrf2/HO-1 Pathway.Neuromolecular medicine · 2025Article
- Research progress on the kidney-gut-brain axis in brain dysfunction in maintenance hemodialysis patients.Frontiers in medicine · 2025Review
- The Impact of Plasma Homocysteine Level and Estimated Glomerular Filtration Rate on Neurological Function at Admission in Patients with Acute Ischemic Stroke: A Retrospective Cross-Sectional Study.Neuropsychiatric disease and treatment · 2025Article
- Regulation of the blood-brain barrier function by peripheral cues in health and disease.Metabolic brain disease · 2024Review
- Combining hemodialysis with peritoneal dialysis improves cognitive function: a three-case report.CEN case reports · 2024Article
- Indoxyl sulfate induces apoptotic cell death by inhibiting glycolysis in human astrocytes.Kidney research and clinical practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals at all stages of chronic kidney disease (CKD) have a higher risk of developing cognitive disorders and dementia. Stroke is also highly prevalent in this population and is associated with a higher risk of neurological deterioration, in-hospital mortality, and poor functional outcomes. Evidence from in vitro studies and in vivo animal experiments suggests that accumulation of uremic toxins may contribute to the pathogenesis of stroke and amplify vascular damage, leading to cognitive disorders and dementia. This review summarizes current evidence on the mechanisms by which uremic toxins may favour the occurrence of cerebrovascular diseases and neurological complications in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.